Publication:
The long non-coding RNA Morrbid regulates Bim and short-lived myeloid cell lifespan

No Thumbnail Available

Date

2016

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

Springer Nature
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Kotzin, Jonathan J., Sean P. Spencer, Sam J. McCright, Dinesh B. Uthaya Kumar, Magalie A. Collet, Walter K. Mowel, Ellen N. Elliott, et al. 2016. “The Long Non-Coding RNA Morrbid Regulates Bim and Short-Lived Myeloid Cell Lifespan.” Nature 537 (7619) (August 15): 239–243. doi:10.1038/nature19346. http://dx.doi.org/10.1038/nature19346.

Research Data

Abstract

Neutrophils, eosinophils and “classical” monocytes collectively account for ~70% ofhuman blood leukocytes and are among the shortest-lived cells in the body. Precise regulation of the lifespan of these myeloid cells is critical to maintain protective immune responses while minimizing the deleterious consequences of prolonged inflammation. However, how the lifespan of these cells is strictly controlled remains largely unknown. Here, we identify a novel long non-coding RNA (lncRNA) that we termed Morrbid, which tightly controls the survival of neutrophils, eosinophils and “classical” monocytes in response to pro-survival cytokines. To control the lifespan of these cells, Morrbid regulates the transcription of its neighboring pro-apoptotic gene, Bcl2l11 (Bim), by promoting the enrichment of the PRC2 complex at the Bcl2l11 promoter to maintain this gene in a poised state. Notably, Morrbid regulates this process in cis, enabling allelespecific control of Bcl2l11 transcription. Thus, in these highly inflammatory cells, changes in Morrbid levels provide a locus-specific regulatory mechanism that allows for rapid control of apoptosis in response to extracellular pro-survival signals. As MORRBID is present in humans and dysregulated in patients with hypereosinophilic syndrome, this lncRNA may represent a potential therapeutic target for inflammatory disorders characterized by aberrant short-lived myeloid cell lifespan.

Description

Other Available Sources

Keywords

Terms of Use

Metadata Only

Endorsement

Review

Supplemented By

Referenced By

Related Stories